Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

M Vital, Edward; T. Merrill, Joan; F. Morand, Eric; Furie, Richard; N Bruce, Ian; Tanaka, Yoshiya; Manzi, Susan; Kalunian, Kenneth; N. Kalyani, Rubana; Streicher, Katie; Abreu, Gabriel; Tummala, Raj

doi:10.1136/annrheumdis-2021-221425

Public

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials

Published in Annals of the Rheumatic Diseases • Mar 25, 2022

Authors:

Edward M Vital

Joan T. Merrill

Eric F. Morand

Abstract

OBJECTIVES: To characterise the efficacy and safety of anifrolumab in patients with systemic lupus erythematosus (SLE) according to interferon gene signature (IFNGS), demographic and clinical subgroups. METHODS: We performed post hoc analyses of pooled data from the 52-week phase III TULIP-1/TULIP-2...

Subject

Medicine

Internal medicine

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!